Sean Koppe

Sean Koppe

Auto-generated profile, based on publicly available information

Sean Koppe

Division of Gastroenterology and Hepatology, University of Illinois at Chicago, Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2018 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
RSRaiya Sarwar
Raiya Sarwar
NPNicholas Pierce
Nicholas Pierce
SKSean Koppe
Sean Koppe
Nonalcoholic fatty liver disease (NAFLD) is rapidly becoming the most common cause of chronic liver disease due to an increase in the prevalence of obesity. The development of NASH leads to an increase in morbidity and mortality. While the first line of treatment is lifestyle modifications, including dietary changes and increased physical activity, there are no approved pharmacological treatment agents for NAFLD and NASH currently. Due to its complex pathophysiology, different pathways are under investigation for drug development with the focus on metabolic pathways, inflammation, and slowing or reversing fibrosis. There are several agents advancing in clinical trials, and promising results have been seen with drugs that affect hepatic steatosis, inflammation, and fibrosis. This review will provide an overview on NAFLD and some of the mechanisms of disease that are being targeted with pharmacologic agents.

1 August 2018 in Clinical and Experimental Gastroenterology
Verified
Journal Article
Open access
PDF file
ZAZohair Ahmed
Zohair Ahmed
UAUmair Ahmed
Umair Ahmed
SWSaqib Walayat
Saqib Walayat
JRJinma Ren
Jinma Ren
DMDaniel K Martin
Daniel K Martin
SDSonu Dhillon
Sonu Dhillon
Background and aims: Many patients with liver disease come to medical attention once they have advanced cirrhosis or acute decompensation. Most often, patients are screened for liver disease via liver function tests (LFTs). There is very limited published data evaluating laboratory values with biopsy-proven stages of hepatic fibrosis. We set out to evaluate whether any correlation exists between routine LFTs and stages of hepatic fibrosis. Methods: A large retrospective observational study on 771 liver biopsies was conducted for evaluating the stage of fibrosis with AST, ALT, INR, BUN, creatinine, platelets, alkaline phosphatase, bilirubin, and albumin. Mean and 95% confidence intervals were used to describe the distributions of serum markers in different fibrosis stages. Multivariable generalized linear models were used and a two-tailed P-value was calculated. Results: ALT was not statistically significant for any stage, and AST was statistically significant for stage 3 and 4 fibrosis. INR was statistically significant only in stage 4 disease but remained near the upper limit of normal range. Albumin failed to show a clinically relevant association. Platelets remained within normal laboratory range for all stages. The remaining laboratory values failed to show statistical and clinical significance. Conclusion: The health care burden from chronic liver disease (CLD) will likely continue to rise, unless clinicians are made aware that normal or near normal laboratory findings may be seen in asymptomatic patients. Earlier identification of asymptomatic patients will allow for treatment with new promising modalities and decrease morbidity and mortality from CLD. Our study shows that laboratory values correlate poorly with liver disease.

1 June 2018 in Gastroenterology Clinics of North America
Verified
Journal Article
Closed access
RKRuben Khan
Ruben Khan
SKSean Koppe
Sean Koppe

11 June 2018 in Cureus
Verified
Journal Article
Open access
PDF file
STSarang Thaker
Sarang Thaker
CYCemal Yazici
Cemal Yazici
SKSean Koppe
Sean Koppe
Pericardial tamponade is a rare cause of acute liver injury due to the compressive effects of an effusion resulting in a poor cardiac output which ultimately leads to ischemia-induced injury. We present a patient with chronic hepatitis C infection and end-stage renal disease who was transferred to our center for further evaluation and management of acute liver injury after presenting to an outside hospital with left upper quadrant abdominal pain, nausea and vomiting. The patient was discovered to have tamponade physiology on transthoracic echocardiogram as an underlying cause of his acute liver injury despite lack of clinical tamponade features. He required pericardiocentesis which eventually led to resolution of the acute liver injury and he was discharged home on day twelve after full recovery. We review the existing literature regarding the epidemiology, pathophysiology, clinical presentation, diagnosis, and treatment of ischemic hepatitis, which is associated with high mortality; therefore early recognition and treatment of the underlying cause are paramount.

1 November 2018 in Clinical Liver Disease
Verified
Journal Article
Open access
PDF file
RKRuben Khan
Ruben Khan
SVSugir Velpari
Sugir Velpari
SKSean Koppe
Sean Koppe
Watch a video presentation of this article

1 January 2018 in Hepatic Medicine: Evidence and Research
Verified
Journal Article
Open access
PDF file
ZAZohair Ahmed
Zohair Ahmed
JRJinma Ren
Jinma Ren
AGAdam Gonzalez
Adam Gonzalez
UAUmair Ahmed
Umair Ahmed
SWSaqib Walayat
Saqib Walayat
SDSonu Dhillon
Sonu Dhillon
Aim: The purpose of this study was to create and validate a novel serological diagnostic index to predict cirrhosis of all etiologies. Methods: This was a retrospective observational study of 771 patients, age >18 years, who underwent a liver biopsy. The stage of fibrosis and routine laboratory values were recorded. The data were randomly separated into 2 datasets (training 50% and testing 50%). A stepwise logistic regression model was used to develop the novel index. The area under the curve of receiver operating characteristic (AUROC) was applied to compare the new index to existing ones (Fibro-Q, FIB4, APRI, AAR), which was also validated in the testing dataset. Results: Variables associated with the presence of cirrhosis were first assessed by univariate analysis then by multivariable analysis, which indicated serum glutamic-oxaloacetic acid transaminase, serum glutamic-pyruvic transaminase, international normalized ratio, albumin, blood urea nitrogen, glucose, platelet count, total protein, age, and race were the independent predictors of cirrhosis (P<0.05). Regression formula for prediction of cirrhosis was generated and a novel index was subsequently created. The diagnostic performance of the novel index for predicting cirrhosis was assessed using the receiver operating characteristic curve. The new index had significantly higher AUROC (0.83, 95% CI: 0.79-0.87) than Fibro-Q (0.80, 95% CI: 0.76.-0.85), FIB4 (0.79, 95% CI: 0.74-.0.83), APRI (0.74, 95% CI: 0.69-.0.78), and AAR (0.72, 95% CI: 0.67-0.78). Conclusion: The novel index had the highest AUROC curve when compared with current indices and can be applied to all etiologies of chronic liver disease.